anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To separate and purify d-biotin in high yield by bringing an aqueous solution containing the d-biotin or/and desthiobiotin into contact with a styrene- based strong basic anion exchange resin and eluting the d-biotin. CONSTITUTION:An aqueous solution containing d-biotin or/and desthiobiotin, e.g. a fermentation liquor or an enzymic reactional solution is brought into contact with a styrene-based strong basic anionic exchange resin having an ion exchange group structure of the dimethylethanolamine type at 5-60 deg.C and pH5-9. Elution is then carried out by using an eluent such as formic acid or acetic acid to afford the objective substance. Diaion SA20Agamma (manufactured by Mitsubishi Kasei Corporation), etc., are preferably used as the ion exchange resin. The d-biotin is useful as medicines, foods, feed additives, etc.
The invention relates to a nanometer grain and rationed nanometer aerosol utilizing the nanometer grain and their preparation method. With comprehensive microemulsion technology and fast drying technology, prepare a plurality of chemical drugs and biologic particles into nanometer grain, so as to enhance the transfer efficiency via lung intake. To be specific, evenly distribute the liquid for dissolving the drug in another non-mixing solvent under the action of surfactant with microemulsion technology. Then, evaporate all the liquid with fast drying technology to get the nanometer grain of drug. The nanometer grain of drug can evenly disperse in a fluid with propellent, so as to get the nanometer preparation of aerosol. The nanometer preparation has stable transfer capacity for the lung intake of drug and can be applied to drugs with lung transfer, oral transfer or nostril transfer.
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
Low back pain is a musculoskeletal symptom which occur in all ages during life time with acute episode or chronic condition. Total of 619 million people are living with low back pain worldwide. Low back pain is the musculoskeletal condition that involves pain in region below costal margin and above inferior gluteal fold, along with pain there is also stiffness, limitation of range of motion, aggravated by movement and affected ability to perform daily life activities. Frequency and severity of low back pain are related to spinal loading that increase the strain on lumbar spine, these loads shift from foot (during heel strike) to leg and ultimately to the back.

Abnormal mechanical loading of lumbar spine due to poor postural control or muscular weakness is considered as risk factor for low back pain. The ability of ankle complex to provide stabilization and mobilization depends upon plantar pressure distribution. In particular, pronated foot causes internal rotation of tibia along with internal rotation of hip that cause femoral ante-version and increase in lumbar lordosis and deteriorate lumbopelvic alignment resulting in low back pain Short foot exercise (SFE) is considered more effective in terms of postural balance and excessive pronation. SFE is a widely used intervention that has been developed recently to improve ankle proprioception and global movement pattern, so as to elevate and support the medial longitudinal arch of the foot and to improve dynamic standing balance Anti-pronation taping is a technique that stimulate underlying sensory receptor either through the surface contact or stretch of skin that causes the sensory input to central nervous system to be altered hence it ultimately influences the execution and perception of movement. Low dye taping is effective in correcting over-pronated foot and also increase navicular height along with increase in reactive strength index. low dye taping not only improve arch height but also improves muscular activity The rationale for the use of these techniques is to compare the effect of short foot exercises and anti-pronation taping on low back pain associated with hyper-pronated foot and also on range of motion of foot and back along with the foot posture.
Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
Here, we describe pathological events potentially involved in the disease pathogenesis of Alexander disease (AxD). This is a primary genetic disorder of astrocyte caused by dominant gain-of-function mutations in the gene coding for an intermediate filament protein glial fibrillary acidic protein (GFAP). Pathologically, this disease is characterized by the upregulation of GFAP and its accumulation as Rosenthal fibers. Although the genetic basis linking GFAP mutations with Alexander disease has been firmly established, the initiating events that promote GFAP accumulation and the role of Rosenthal fibers (RFs) in the disease process remain unknown. Here, we investigate the hypothesis that disease-associated mutations promote GFAP aggregation through aberrant posttranslational modifications. We found high molecular weight GFAP species in the RFs of AxD brains, indicating abnormal GFAP crosslinking as a prominent pathological feature of this disease. In vitro and cell-based studies demonstrate that cystine-generating mutations promote GFAP crosslinking by cysteine-dependent oxidation, resulting in defective GFAP assembly and decreased filament solubility. Moreover, we found GFAP was ubiquitinated in RFs of AxD patients and rodent models, supporting this modification as a critical factor linked to GFAP aggregation. Finally, we found that arginine could increase the solubility of aggregation-prone mutant GFAP by decreasing its ubiquitination and aggregation. Our study suggests a series of pathogenic events leading to AxD, involving interplay between GFAP aggregation and abnormal modifications by GFAP ubiquitination and oxidation. More important, our findings provide a basis for investigating new strategies to treat AxD by targeting abnormal GFAP modifications.
Servers of a clinical trial support network have digital data processors which execute an automated tracking and prediction model for patient engagement. The model is linked with an interfacing tool used by doctor managing a group of patients and an interfacing tool used by patients for real time capture of events. The system processes factor values to generate and track in real time a patient engagement index. The system uses the factor values to maintain a taxonomy of factor values. The system is also programmed to determine values of characteristics derived from the factors, such as a characteristic indicating time-based trend of a factor. Another advantageous characteristic is impact of multiple occurrences of a factor.
Sexually transmitted diseases (STDs), including HIV infections, are most commonly spread through unprotected sexual intercourse. STDs are a major health concern, especially among young ethnic minorities in the United States. The rate of STDs is significantly greater in urban areas where ethnic minorities, particularly African-American males, are commonly represented. Despite this knowledge, safe sexual practices, including correct condom use, are not the norm among minority males. It is believed that educational outreach designed to motivate and inform on the correct use of condoms will be effective in encouraging safer sex practices. This study will test the effectiveness of a brief clinic-based program designed to promote the correct use of condoms among young African-American men newly diagnosed with an STD.

Participants in this single blind study will be randomly assigned to an experimental or control group. Upon being diagnosed with an STD, men in both groups will receive standard of care follow-up treatment. Men in the experimental group will also receive a one-on-one educational session on condom use. The educational session will be led by a health educator and will last about 30 minutes, depending on the existing skills and learning abilities of the participants. Using information provided by the participants on past experience with condoms, the health educator will attempt to correct misunderstandings about and problems with condom use. Upon enrollment, all men will respond to a series of pre-recorded questions and will be required to demonstrate their ability to apply condoms to a penile model. The same questions and procedure will be repeated 3 months later.
Trans-arterial chemoembolization (TACE) is a standard care of intermediate stage Hepatocellular carcinoma (HCC) for 40 years without much improvement in efficacy. The key reason for lack of progress is that chemotherapy agents are not effective in hypoxia and cancer stem cells are induced under hypoxia. Tirapazamine, a hypoxia activated agent, can potential solve these two problems. This open label randomized trial will be conducted in HCC patients who are in intermediate stage and naive to embolization, Child Pugh up to B7 and with normal organ functions. Patients will be randomized 1:1 to receive TATE (trans-arterial tirapazamine embolization) or conventional TACE. The goal of treatment aims to achieve CR by mRECIST for every patient. If there is evidence of viable lesion, patients should be treated again. All patients are followed by contrast MRI scans every 2 months in the first year and every 3 months afterwards until patients have evidence of progression and no longer considered suitable for TATE/TACE. Survival will be followed for 3 years. Total sample size will be 134 patients with the total study duration for 3 years.
Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
BACKGROUND: Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but challenges remain in its utilization as a biomarker. This study aimed to investigate salivary CGRP levels during migraine attacks across the frequency spectrum and explore associations with clinical variables.
METHODS: A prospective longitudinal pilot study was conducted, recruiting migraine patients from an outpatient headache clinic. Salivary CGRP levels were measured at interictal, onset, post-2 h of onset and end-of-attack. Using generalized linear mixed models, we explored the effect of CGRP changes over the attack in presence of depressive symptoms (DS), acute attack treatment, and after three-months of erenumab treatment. Finally, patients were classified and compared according to their CGRP phenotype.
RESULTS: A total of 44 migraine patients were included (90.9% women), with 80 migraine attacks analyzed. Salivary CGRP levels increased at the onset of migraine attacks. We observed statistically significant interactions between DS and both the linear (Est. [SE]: 19.4 [5.8], p = 0.001) and quadratic terms of time (-19.1 [6.0], p = 0.002). Additionally, a significant three-way interaction within the use of acute treated attack (linear-term: -18.5 [6.2], p = 0.005; quadratic-term: 19.2 [6.8], p = 0.005) was also found. Molecular phenotyping revealed that 72.7% (32/44) of patients presented only CGRP-dependent attacks, while 27.3% (12/44) presented non-CGRP-dependent migraine attacks. Patients with only CGRP-dependent attacks were associated with younger age, shorter disease evolution time, a higher proportion of aura, and fewer monthly headache days (p < 0.05). Exploratory analysis of erenumab treatment effects did not result in changes in CGRP levels during migraine attacks.
CONCLUSIONS: Our study underscores the dynamic nature of migraine at a molecular level and emphasizes the importance of integrating clinical variables, such as depressive symptoms, in understanding its pathophysiology. The identification of distinct migraine subtypes based on CGRP dependence suggests potential opportunities for personalized treatment approaches.
Safety and effectiveness of Venofer for iron replacement treatment in pediatric patients with dialysis-dependent or non-dialysis-dependent CKD have not been established. 

Safety and effectiveness of Venofer for iron maintenance treatment in pediatric patients 2 years of age and older with dialysis-dependent or non-dialysis-dependent CKD receiving erythropoietin therapy were studied. Venofer at doses of 0.5 mg/kg, 1 mg/kg, and 2 mg/kg was administered. All three doses maintained hemoglobin between 10.5 g/dL and 14.0 g/dL in about 50% of subjects over the 12-week treatment period with stable EPO dosing [see Clinical Studies (14.7)].

Venofer has not been studied in patients younger than 2 years of age. 

In a country where Venofer is available for use in children, at a single site, five premature infants (weight less than 1,250 g) developed necrotizing enterocolitis and two of the five died during or following a period when they received Venofer, several other medications and erythropoietin. Necrotizing enterocolitis may be a complication of prematurity in very low birth weight infants. No causal relationship to Venofer or any other drugs could be established.
Empiric administration of phytonadione should not replace proper laboratory evaluation of the coagulation mechanism. A prompt response (shortening of the prothrombin time in 2 to 4 hours) following administration of phytonadione is usually diagnostic of hemorrhagic disease of the newborn, and failure to respond indicates another diagnosis or coagulation disorder. 

Phytonadione injectable emulsion 1 mg should be given either subcutaneously or intramuscularly. Higher doses may be necessary if the mother has been receiving oral anticoagulants.

Whole blood or component therapy may be indicated if bleeding is excessive. This therapy, however, does not correct the underlying disorder and phytonadione injectable emulsion should be given concurrently.
α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and/or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.
PURPOSE:To obtain a hyaluronidase inhibitor, consisting essentially of a substance prepared by hydrolyzing a mucilage of shellfishes, having lubricity and softness of the skin and capable of preventing bacterial infection and aging. CONSTITUTION:This hyaluronidase inhibitor comprises a substance prepared by, as necessary, subjecting a mucilage of shellfishes, preferably Pictada martensii to precipitating treatment, hydrolyzing the resultant substance with an acid (e.g. hydrochloric acid), an alkali (e.g. NaOH) or an enzyme, converting the mucilaginous ingredient into a low-molecular substance, desalting the obtained substance or desalting the substance and then hydrolyzing the desalted substance as a principal ingredient. The desalting is preferably carried out by washing the low-molecular substance with water or an aqueous solution of ethanol or treating the substance by a chromatographic method, etc., using an ion exchange resin. Remarkable suppressing effects on the hyaluronidase activity are recognized in the mucilage hydrolyzate of the shellfishes and the hydrolyzate prevents the hyaluronic acid from decomposing and contributes to the stabilization. Thereby, the skin is prevented from forming small wrinkles and drying up due to the aging and the gloss and tenseness of the skin are kept good.
An Intensol is a concentrated oral solution as compared to standard oral liquid medications. It is recommended that an Intensol be mixed with liquid or semi-solid food such as water, juices, soda or soda-like beverages, applesauce and puddings.

Use only the calibrated oral syringe provided with this product. Draw into the oral syringe the amount prescribed for a single dose. Then empty the contents of the oral syringe into a liquid or semi-solid food, by depressing the plunger until the barrel is empty. Stir the liquid or food gently for a few seconds. The Intensol formulation blends quickly and completely. The entire amount of the mixture, of drug and liquid or drug and food, should be consumed immediately. Do not store for future use.
Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
A hair treatment composition is disclosed. The composition comprises: (A) a branched-type quaternary ammonium salt, (B) one or more agents selected from the group consisting of oxidizing agents, reducing agents, and dyeing agents, and (C) a higher alcohol having a branched ratio of 1-50%. The composition is directed to hair perming, hair dyeing, and the like, and exhibits excellent hair protecting and hair conditioning effects even under severe conditions. It features good handling performance, e.g. the capability of preventing running of the liquid and of providing superior spreadability. The excellent conditioning effect lasts for a long period of time even after repeated washing.
Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
Perioperative monitoring system 100 including: selection module 102 configured to receive operation requirements; database of conditions 105; condition module 104 responsive to the selection module and in communication with the database; and a validation system 106 that receives the selected conditions from the condition module and determines a validation. The condition module is configured to select conditions from the database based on the received operational requirements. The validation system includes a filter that filters selected conditions based on a functional selection in order to provide a functional configuration. Monitoring system may include a lock module that unlocks a context based on the validation. Monitoring system may include two or more validation systems each associated with respective functional configuration, and may determine successful system validation based on validation of at least two of the functional configurations. Also disclosed is a perioperative multi-stage validation system including: a function unit configured to provide a functional selection; a filter that filters selected conditions in a database of conditions based on the functional selection in order to provide a functional configuration; a sensor input that provides a parameter for validation; and a validator that validates the parameter against the functional configuration to provide a validation.
Participants will be undergraduate students randomly assigned to either being in the mentor or comparison group. A second set of participants will be randomly assigned to either being in the mentee or comparison group. These participants will come from Chicago Public School elementary schools. In total, there will be 125 mentors, 125 comparators, 125 mentees, and 125 comparators. Participants will come for a laboratory visit in which cardiovascular health measures will be taken (details below). Visits will occur once at baseline (before the intervention starts), and once post-intervention. There will be a mid-point assessment of questionnaires. Participants in the intervention group will engage in one-on-one mentoring sessions (mentors together with mentees) once a week after school for the school year. Participants in the comparator group will receive written versions of all materials covered in the mentoring sessions.
The invention discloses application of a substance for regulating and controlling protein gene expression in preparing a sensitizer for a tumor chemotherapeutic drug, and belongs to the technical field of biology. The protein is ubiquitin carboxyl terminal esterase L3, and the amino acid sequence of the protein is shown in SEQ ID No. 1. The protein can be used for preparing a sensitizer of a tumor chemotherapeutic medicament or a medicament for reducing the sensitivity of the tumor chemotherapeutic medicament or preparing the tumor medicament, wherein the chemotherapeutic medicament is 5-fluorouracil, and the tumor generates TP53 mutation. Experiments prove that ubiquitin carboxyl terminal esterase L3 participates in mediating dryness characteristic maintenance and 5-FU chemotherapy resistance caused by colorectal cancer TP53 gene mutation. The Pacritinib drug significantly enhances the sensitivity of TP53 mutant colorectal cancer to 5-FU chemotherapy by inhibiting UCHL3 expression.
Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using "Optimal PEEP" determined by Electrical Impedance and FIO2 of 0.5.
PURPOSE: A composition and a cosmetic composition containing a Piperis Nigri Fructus extract are provided to induce the apoptosis of pancreatic cancer cells, and to effectively treat pancreatic cancer. CONSTITUTION: A composition and a cosmetic composition for treating pancreatic cancer contains a Piperis Nigri Fructus extract as an active ingredient. The extract is prepared using ethanol at 50 deg. C. for 24 hours. The extract is dried and concentrated by a reduced pressure at 45 deg. C. The composition contains a pharmaceutically acceptable carrier or diluents. The pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cellular viability